The efficacy of different warfarin starting doses (3 mg versus 5 mg) and the corresponding dosing schedule in patients diagnosed with deep vein thrombosis
- Conditions
- The efficacy of different warfarin initiating dose in patients diagnosed with venous thromboembolismwarfarin,initiating dose,efficacy,venous thromboembolism
- Registration Number
- TCTR20180328002
- Lead Sponsor
- Faculty of Medicine Siriraj Hospital, Mahidol University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Active, not recruiting
- Sex
- All
- Target Recruitment
- 56
Adult patients aged 18 years or older who were diagnosed with symptomatic proximal deep vein thrombosis (DVT) of the extremity or DVT at other unusual sites (for example, cerebral venous sinus thrombosis, and/or pulmonary embolism (PE)) and planned to receive warfarin with a target INR of 2.0â€3.0.
An absolute contraindication to anticoagulant therapy (e.g., active bleeding), high risk of bleeding (e.g., recent eye, brain or spinal cord surgery within 3 months), history of concurrent congestive heart failure, history of liver cirrhosis (Child Pugh class B or C), concomitant use of aspirin, prolonged baseline PT and/or activated partial thromboplastin time (aPTT) above the upper normal limits, platelet counts of less than 50×109/L, serum albumin less than 2.0 g/dL, pregnancy, and patients who were unable to perform oral feeding
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Efficacy of warfarin initiating dose and the corresponding dosing schedule 8 days The number of patients who achieved the INR of 2.0â€3.0 within 8 days after treatment
- Secondary Outcome Measures
Name Time Method Bleeding complication 8 days The incidence of bleeding complications within 8 days or INR > 5.0 ,Characteristics of CYP2C9 and VKORC1 single nucleotide polymorphisms 8 days Genotyping of CYP2C9 and VKORC1